Xconomy | Seattle - Business + Technology in the Exponential Economy

Immune Design Aiming To Make Vaccines That Work Better in a Single Shot
Out With the Old Shots, In With the New: Xconomy Forum To Explore Disruptive Changes in Vaccines
Announcing Xconomy’s First Event in Seattle: Vaccines 2.0
Immune Design, Led By Star Scientists, Raises $18 Million To Build Vaccine Company
Vaccines Force Their Way off Pharma’s Back Burner, as Price Increases Help Fuel New Wave of Innovation

Immune Design Obtains Vaccine Booster From IDRI

Immune Design, the Seattle-based vaccine development company, has obtained a worldwide exclusive license to develop a vaccine-boosting compound invented at the Infectious Disease Research Institute (IDRI). The technology, a glycopyranosyl lipid adjuvant, may be used to enhance the effectiveness of vaccines. The nonprofit IDRI will receive an upfront payment, milestone payments on success in testing, and royalties from sales if it ever turns into a product, as well as shares in Immune Design, a startup that raised $18 million in a Series A venture round in June.

Luke Timmerman is the National Biotechnology Editor for Xconomy. You can email him at ltimmerman@xconomy.com or call 206-624-2374.

Comments | Permalink |